Phaseline

Companies › Shenyang Sunshine Pharmaceutical

Shenyang Sunshine Pharmaceutical: clinical trials, targets and expected readouts

12 active drug programs in 15 registered trials: 8 Phase 1, 6 Phase 2, 1 Phase 3; Oncology, Other, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SSGJ-707–Phase 3Advanced Non-Small Cell Lung CancerDec 2028
SSGJ-705
Anti-PD-1 and anti-HER2 bispecific antibody
PDCD1, ERBB2Phase 2Locally Advanced, Recurrent or Metastatic Malignancies; Locally Advanced (Unresectable) or Metastatic Solid TumorsDec 2026
SSGJ-612
HER2-targeting agent
ERBB2Phase 2Locally Advanced (Unresectable) or Metastatic Solid Tumors; Metastatic Breast Cancer; Advanced Malignant TumorsJun 2027
SSGJ-706
PD-1/PD-L1 bispecific antibody
PDCD1, CD274Phase 2First-line Advanced NSCLC PatientsAug 2027
HER2-targeted ADC
HER2-targeted antibody-drug conjugate
ERBB2Phase 2Metastatic Breast CancerFeb 2028
SSS55 injection
complement C3b inhibitor
C3Phase 1Safety IssuesDec 2026
SSS11 (Pegylated Recombinant Candida Utilis Uricase)
Urate oxidase - converts uric acid to allantoin
XDHPhase 1GoutDec 2026
SSS59
humanized antibody targeting MUC17
MUC17Phase 1Malignant TumorsMar 2027
SPGL008
Biological product
–Phase 1Advanced Malignant TumorsJun 2027
HBT-708
bispecific antibody
–Phase 1Advanced Solid TumorsJun 2027
SSGJ-709
Bispecific antibody targeting PD-1 and LAG-3
PDCD1, LAG3Phase 1Advanced Malignant TumorsSep 2027
SSS40
Humanized nerve growth factor (NGF) antibody
NGFPhase 1Cancer Pain–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07008703SSS40Phase 1Cancer PainOncologyDec 2025
NCT07032298SSGJ-612Phase 1Advanced Malignant TumorsOncologyApr 2026
NCT07058779SSS55 injectionPhase 1Safety IssuesOtherDec 2026
NCT06629376SSS11 (Pegylated Recombinant Candida Utilis Uricase)Phase 1GoutMetabolic and endocrineDec 2026
NCT07022002SSGJ-705Phase 2Locally Advanced, Recurrent or Metastatic MalignanciesOncologyDec 2026
NCT06944444SSS59Phase 1Malignant TumorsOncologyMar 2027
NCT07038005SPGL008Phase 1Advanced Malignant TumorsOncologyJun 2027
NCT06993870HBT-708Phase 1Advanced Solid TumorsOncologyJun 2027
NCT07646626SSGJ-612Phase 2Locally Advanced (Unresectable) or Metastatic Solid TumorsOncologyJun 2027
NCT07646626SSGJ-705Phase 2Locally Advanced (Unresectable) or Metastatic Solid TumorsOncologyJun 2027
NCT07171606SSGJ-706Phase 2First-line Advanced NSCLC PatientsOncologyAug 2027
NCT07016490SSGJ-709Phase 1Advanced Malignant TumorsOncologySep 2027
NCT07757230SSGJ-612Phase 2Metastatic Breast CancerOncologyFeb 2028
NCT07757230HER2-targeted ADCPhase 2Metastatic Breast CancerOncologyFeb 2028
NCT06980272SSGJ-707Phase 3Advanced Non-Small Cell Lung CancerOncologyDec 2028

Targets

PDCD1 (3) ERBB2 (3) NGF (1) CD274 (1) C3 (1) LAG3 (1) XDH (1) MUC17 (1)

Companies with the same targets

Shanghai Henlius Biotech Akeso Roche Beijing Biotech AstraZeneca Sichuan Baili Pharmaceutical Pfizer Innovent Biologics (Suzhou) Jiangsu HengRui Medicine Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Shanghai Henlius Biotech Sichuan Baili Pharmaceutical DualityBio Shanghai Hengrui Pharmaceutical Akeso

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.